{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T06:40:26Z","timestamp":1777876826722,"version":"3.51.4"},"reference-count":67,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Med Oncol"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The 5-year overall survival rates in acute lymphoblastic leukemia (ALL) vary depending on the patient\u2019s age group (from 93% to under 30%). However, in the case of relapsed\/refractory ALL (R\/R ALL), the complete remission (CR) rate in the pediatric patient group is 44% and in the adult population\u201418%. Therefore, further research on new therapeutic compounds is necessary.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>This systematic review aims to analyze the results of clinical studies concerning the use of venetoclax alone or in combination with other drugs in the treatment of ALL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>The systematic review was conducted in accordance with the guidelines of Preferred Reporting Items for Systematic Reviews and Meta-Analysis. The Quality Assessment Tool for Before-After (Pre-Post) Studies With No Control Group by the National Heart, Lung, and Blood Institute was used to assess the quality of included studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources and methods:<\/jats:title>\n                    <jats:p>PubMed and Web of Science were used for the literature review. All clinical studies reporting outcomes in patients with ALL treated with venetoclax met the inclusion criteria. As a result of our search process for articles, a total of 989 records were obtained. After excluding records that did not meet the inclusion criteria or met the exclusion criteria, seven articles were finally obtained.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>In seven identified clinical trials, CR rate ranged from 22% to 59.6% in patients with R\/R ALL, while in the group of patients with newly diagnosed ALL, it ranged from 90.9% to 96%. The most common adverse events of grade 3 or higher were hematological complications, including neutropenia (71 episodes among 110 patients), anemia (70\/141), and thrombocytopenia (70\/141).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Based on the results of phase I clinical trials, further clinical trials should be conducted to assess the therapeutic potential of venetoclax in the treatment of ALL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17588359251403912","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T16:06:20Z","timestamp":1767888380000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["The use of venetoclax in the treatment of acute lymphoblastic leukemia\u2014a systematic review"],"prefix":"10.1177","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3832-7941","authenticated-orcid":false,"given":"Adrian","family":"Kowalczyk","sequence":"first","affiliation":[{"name":"Doctoral School, Medical University of Lublin, Lublin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9765-376X","authenticated-orcid":false,"given":"Julia","family":"Zarychta","sequence":"additional","affiliation":[{"name":"Doctoral School, Medical University of Lublin, Lublin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7207-156X","authenticated-orcid":false,"given":"Joanna","family":"Zawitkowska","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology, Oncology and Transplantology, Medical University of Lublin, Lublin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8760-0775","authenticated-orcid":false,"given":"Monika","family":"Lejman","sequence":"additional","affiliation":[{"name":"Independent Laboratory of Genetic Diagnostics, Medical University of Lublin, Lublin 20-093, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/jleuko\/qiae015"},{"key":"e_1_3_4_3_2","unstructured":"National Cancer Institute. Surveillance epidemiology and end results program. Cancer Stat Facts: Leukemia \u2014 Acute Lymphoblastic Leukemia (ALL) https:\/\/seer.cancer.gov\/statfacts\/html\/alyl.html (2025 accessed 27 June 2025)."},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxlet.2024.08.010"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1289\/ehp.9023"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26156"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-1465"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11684-020-0759-8"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1177\/10732748211019138"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-022-00661-9"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.2174\/156652408783769599"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2012.12.013"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231810957"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-04900-y"},{"key":"e_1_3_4_15_2","unstructured":"Food and Drug Administration. FDA approves venetoclax for CLL or SLL with or without 17 p deletion after one prior therapy https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-venetoclax-cll-or-sll-or-without-17-p-deletion-after-one-prior-therapy (2018 accessed 27 June 2025)."},{"key":"e_1_3_4_16_2","unstructured":"Food and Drug Administration. FDA approves venetoclax for CLL and SLL https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-venetoclax-cll-and-sll (2019 accessed 27 June 2025)."},{"key":"e_1_3_4_17_2","unstructured":"Food and Drug Administration. FDA approves venetoclax in combination for AML in adults https:\/\/www.fda.gov\/drugs\/fda-approves-venetoclax-combination-aml-adults (2018 accessed 27 June 2025)."},{"key":"e_1_3_4_18_2","unstructured":"Food and Drug Administration. FDA grants regular approval to venetoclax in combination for untreated acute myeloid leukemia https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-regular-approval-venetoclax-combination-untreated-acute-myeloid-leukemia (2020 accessed 27 June 2025)."},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-574566"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.377"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-1849"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-707414"},{"key":"e_1_3_4_23_2","unstructured":"National Institutes of Health (NIH). Study Quality assessment tools. National Heart Lung and Blood Institute https:\/\/www.nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools (2021 accessed 21 March 2025)."},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023012231"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-024-05775-z"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.991"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024014405"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.31630"},{"issue":"5","key":"e_1_3_4_29_2","first-page":"1105","article-title":"Venetoclax in combination with a pediatric-inspired regimen for the treatment of newly diagnosed adults with Philadelphia chromosome-negative acute lymphoblastic leukemia","volume":"110","author":"Aldoss I","year":"2025","unstructured":"Aldoss I, Zhang J, Shimamoto K, et al. Venetoclax in combination with a pediatric-inspired regimen for the treatment of newly diagnosed adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. Haematologica 2025; 110(5): 1105\u20131114.","journal-title":"Haematologica"},{"key":"e_1_3_4_30_2","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PB, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372: n71.","journal-title":"BMJ"},{"key":"e_1_3_4_31_2","unstructured":"American Cancer Society. Treatment of Children with Acute Lymphocytic Leukemia (ALL) https:\/\/www.cancer.org\/cancer\/types\/leukemia-in-children\/treating\/children-with-all.html (2025 accessed 4 July 2025)."},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0051"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40267-016-0346-x"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-023-05083-y"},{"key":"e_1_3_4_35_2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2020-141766","article-title":"Daratumumab and venetoclax-containing regimens in the management of relapse after allogeneic hematopoietic stem cell transplantation in hematological malignancies","volume":"136","author":"Yang F","year":"2020","unstructured":"Yang F, Li Z, Dong C, et al. Daratumumab and venetoclax-containing regimens in the management of relapse after allogeneic hematopoietic stem cell transplantation in hematological malignancies. Blood 2020; 136: 9.","journal-title":"Blood"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-021-00343-3"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.14740\/jh2092"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-02-791350"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-02057-x"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-14-0353"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70261-8"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2007.01.037"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-0863"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024013423"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.112615"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3090"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-04042-7"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2025.123347"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c01234"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-0028"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0201-2"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1397"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.9b00568"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.1021\/ml5001867"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2022.109978"},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2016.07.022"},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-175"},{"key":"e_1_3_4_58_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-12-192039"},{"issue":"1","key":"e_1_3_4_59_2","first-page":"6","article-title":"FLT3 Gene involvement in B-cell acute lymphoblastic leukemia (B-ALL)","volume":"47","author":"Okabe A","year":"2021","unstructured":"Okabe A, Guirales F, Zhao D, et al. FLT3 Gene involvement in B-cell acute lymphoblastic leukemia (B-ALL). J Assoc Genet Technol 2021; 47(1): 6\u201314.","journal-title":"J Assoc Genet Technol"},{"key":"e_1_3_4_60_2","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.20502"},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2006.02.004"},{"key":"e_1_3_4_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2019.05.008"},{"key":"e_1_3_4_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2015.12.003"},{"key":"e_1_3_4_64_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023012041"},{"key":"e_1_3_4_65_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06864-7"},{"key":"e_1_3_4_66_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24055004"},{"key":"e_1_3_4_67_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-560284"},{"key":"e_1_3_4_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2022.101354"}],"container-title":["Therapeutic Advances in Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359251403912","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17588359251403912","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359251403912","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:33:55Z","timestamp":1777588435000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17588359251403912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":67,"alternative-id":["10.1177\/17588359251403912"],"URL":"https:\/\/doi.org\/10.1177\/17588359251403912","relation":{},"ISSN":["1758-8359","1758-8359"],"issn-type":[{"value":"1758-8359","type":"print"},{"value":"1758-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"article-number":"17588359251403912"}}